|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 750 9th Street, NW |
Address2 | Suite 575 |
City | Washington |
State | DC |
Zip Code | 20001-4584 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 57954-12
|
||||||||
|
6. House ID# 352640002
|
TYPE OF REPORT | 8. Year | 2010 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Andrea Wilkinson, Director, Federal Governmental Affairs |
Date | 01/20/2011 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
HR 2997 FY 2010 Agriculture Appropriations; FY 2010 Homeland Security Department; FY 2010 Commerce State Justice Appropriations; HR 4899 House Supplemental Appropriations; Continuing Resolutions H3801, HJRes 101, HJRes 105; H3802 through 3/4/11; 2010 Debt Commission
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrea |
Wilkinson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, mental health parity, value based insurance design, quality of care, adhereance, HR 4899 Supplemental Approprations, HCR implementation; Anit-Gout USP matters; Comparative Effectiveness/PCORI; Essential benefits package, ESRD bundling implementation; coverage gap
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrea |
Wilkinson |
|
|
|
Laura |
Cline |
|
|
|
Deborah |
Walter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S. 515, S. 610 and HR 1260 Patent Reform Acts, general patent reform and settlement issues, general follow-on-biologic issues, S 1796 America's Healthy Future Act of 2009; Kerry Patent Tax amendment; HR 3590 Patient Protection and Affordable Care Act, HR 4899 House Supplemental Appropriations; Senate Financial Services Approproations mark up
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrea |
Wilkinson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
HR 4899 Supplemental Appropriations (340B-1 and AMP), Part D coverage gap implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform (see HCR bills); End Stage Renal Disease final rules; TRICARE, HR 684/S330 Medicare prescription drug price negotiation Act of 2010, HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act, Tax Extenders bills, HR 904 Medicaid Prescription Drug Rebate Equalization
340B expansion; PCORI
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Agency for Health Care Policy & Research, Health Resources & Services Administration (HRSA), Defense - Dept of (DOD), Medicare Payment Advisory Commission (MedPAC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrea |
Wilkinson |
|
|
|
Laura |
Cline |
|
|
|
Deborah |
Walter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MAN
16. Specific lobbying issues
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues, HR 4678 Foreign Manufacturers Legal Accountiblity Act; H.R. 6543 The Drug Safety Enhancement Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrea |
Wilkinson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; Importation issues, S. 1232 Preserve Access to Affordable Generics Act; HR 5175 DISCLOSE Act; HR 4678 Foreign Manufacturers Legal Accountiblity Act ; S525 Pharmaceutical Market Access & Drug Safety
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrea |
Wilkinson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
HR 3590 Patient Protection and Affordable Care Act; International tax implications and potential corporate tax reform; Research and Development tax credit and Extenders bills, HR 4872 Health Care and Education Reconcilation Act, HR 3962, HR 4213 The American Jobs & Closing Tax Loophole Act; The Tax Relief, Unemployment Insurance Reauthorization, and Job Creation Act of 2010 (the Act); R&D tax credit; daycare center tax credit; Individual tax credits; Pharmaceutical fee
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrea |
Wilkinson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |